Synthesis and Biological Evaluation of RGD-Conjugated MEK1/2 Kinase Inhibitors for Integrin-Targeted Cancer Therapy

Two novel series of RGD-MEKI conjugates derived from a MEK1/2 kinase inhibitor—PD0325901—have been developed for integrin receptor mediated anticancer therapy. The first series, alkoxylamine analog RGD-MEKI conjugates 9a–g showed anti-proliferation activity in melanoma A375 cells by the same mechani...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaoxiao, Hou, Jianjun, Wang, Chao, Liu, Xinjie, He, Hongyan, Xu, Ping, Yang, Zhenjun, Chen, Zili, Wu, Yun, Zhang, Lihe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269693/
https://www.ncbi.nlm.nih.gov/pubmed/24225774
http://dx.doi.org/10.3390/molecules181113957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269693/
https://www.ncbi.nlm.nih.gov/pubmed/24225774
http://dx.doi.org/10.3390/molecules181113957

Ejemplares similares